How to Apply to Oxford Nanopore

Oxford Nanopore Technologies (LSE: ONT) is a UK-headquartered genomics company that designs, manufactures, and sells nanopore-based DNA and RNA sequencing platforms. Spun out of the University of Oxford in 2005 by chemistry professor Hagan Bayley, Gordon Sanghera, and Spike Willcocks (with backing from Oxford University's then-Isis Innovation, now Oxford University Innovation), the company has spent two decades commercialising a single, audacious idea: read genetic material in real time by threading single molecules through protein nanopores embedded in a synthetic membrane and measuring the tiny ionic current disruptions each base causes. That bet turned into the MinION, the first hand-held DNA sequencer to ship at scale; the desktop GridION; the production-scale PromethION; the Flongle adapter for low-cost runs; and the recently launched P2 Solo, which brings PromethION-class chemistry into a benchtop form factor that runs from a laptop. Headquartered at the Oxford Science Park with additional sites in Cambridge (UK), Cambridge (Massachusetts), New York, Singapore, and Beijing, the company employs roughly 1,000 people across R&D, manufacturing, commercial, software, and support functions. Financially, Oxford Nanopore is one of the most-watched genomics stories in Europe, and not for entirely happy reasons. The September 2021 LSE IPO valued the company at approximately £4.3 billion and was held up as a flagship British deep-tech listing. Since then the share price has been under sustained pressure, and the market capitalisation drifted to roughly £900 million by 2024 as growth from the COVID-era surveillance boom normalised, customer concentration concerns surfaced, and the company pushed out its profitability timeline. Founder-CEO Gordon Sanghera, an electrochemist who previously co-founded glucose biosensor company Sensormetrix (later MediSense) before joining Oxford Nanopore as one of its first hires in 2005, has publicly framed the current period as a strategic pivot rather than a setback: doubling down on the platform's structural advantages in long-read, real-time, portable, and direct-RNA sequencing while building out higher-margin applied markets in clinical diagnostics, biopharma manufacturing QC, biosurveillance, and increasingly mDNA/mRNA therapeutics workflows. The 2024-2025 product cadence, including the Pulselight chemistry rollout aimed at higher accuracy and longer reads and the P2 Solo's expansion of the addressable bench-scale customer base, is the technical expression of that strategy. Commercially, the competitive picture is honest and worth stating: Illumina remains the dominant short-read incumbent with the NextSeq and NovaSeq platforms entrenched in nearly every large sequencing centre; Pacific Biosciences (PacBio) competes head-on in long reads with HiFi chemistry that holds an edge on raw single-read accuracy for many applications. Oxford Nanopore's defensible territory is real-time streaming data, very long reads (multi-hundred-kilobase and even megabase-scale when sample prep allows), native modification calling without bisulfite conversion, direct RNA sequencing, and the ability to generate sequence anywhere there is a USB-C port, from an Antarctic field station to a hospital ward to a bioreactor floor. People who succeed here understand that the company is not trying to be a cheaper Illumina; it is trying to make sequencing a routine measurement layer in places sequencing has never lived before. That mission attracts molecular biologists, electrochemists, ASIC designers, polymer chemists, machine-learning engineers working on basecalling neural networks, and clinical and regulatory specialists building IVD-track products on a platform originally born in a research lab.